Topiramate-Actavis (Topiramate)

Therapeutic indications:

Epilepsy

Topiramate-Actavis is indicated in adults and children 2 years and over:

• as monotherapy in patients with newly diagnosed epilepsy
• for conversion to monotherapy in patients with epilepsy
• as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome.

Migraine

Topiramate-Actavis is indicated in adults for the prophylaxis of migraine headache.

Adverse event reporting

Please ensure any suspected adverse events and other safety information related to Topiramate-Actavis are reported through the appropriate channels, including Medsafe (https://pophealth.my.site.com/carmreportnz/s) and/or Teva’s Medical Information (email: Medinfo.ANZ@tevapharm.com), to support patient safety and continuous quality improvement.

Before prescribing, please review full Data Sheet available at:

https://www.medsafe.govt.nz/profs/Datasheet/t/topiramateactavistab.pdf

References: 

1. Topiramate Actavis Data Sheet. Available at: https://www.medsafe.govt.nz/profs/Datasheet/t/topiramateactavistab.pdf (accessed July 2025).
2. BPAC NZ. Contraception: which option for which patient? Available at: https://bpac.org.nz/2021/contraception/options.aspx (accessed July 2025).
3. Topiramate-Actavis Consumer Medicine Information. Available at: https://www.medsafe.govt.nz/Consumers/CMI/t/topiramateactavis.pdf (accessed July 2025).